Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook

Jefferies reiterated its Buy rating and $30 price target on Sarepta Therapeutics, implying more than 40% upside from the $20.87 share price, while flagging that pivotal functional efficacy data for SRP-1003 may take longer to emerge. The firm estimates competitive or superior six-month splicing and vHOT data in 2H 2026 could move SRPT shares by 25%-50%, with further upside if functional outcomes are clear. Sarepta also beat Q2 2026 expectations with EPS of $0.64 versus $0.22 consensus and revenue of $401.3 million versus $383 million, although total sales declined amid weaker ELEVIDYS demand.

Analysis

SRPT is no longer primarily an earnings-revision trade: the near-term valuation floor depends on whether declining ELEVIDYS demand is transitory channel normalization or evidence that prescriber confidence, patient selection, and reimbursement have structurally weakened. The reported profit beat appears partly cost-control and collaboration-revenue driven, neither of which supports the same multiple as durable product growth. Until management quantifies treatment-center ordering trends and payer approval cadence, the market is likely to discount pipeline optionality heavily.

The pivotal distinction for SRP-1003 is biomarker translation. Strong splicing/vHOT data without an early directional signal in functional endpoints would preserve scientific plausibility but leave commercial adoption and pricing assumptions vulnerable, particularly after the sector has become less willing to capitalize surrogate endpoints at peak probability of success. A clean functional trend could rerate SRPT sharply over 1-3 months around the data release; equivocal biomarkers could compress the stock despite technically positive results because the relevant downside is a delayed commercialization timeline, not necessarily program failure.

A non-obvious competitive read-through is for Avidity Biosciences (RNA): any evidence that SRPT's approach produces differentiated functional benefit would challenge the premium assigned to RNA's del-desiran opportunity, while a merely biomarker-positive SRPT update strengthens the argument that RNA's delivery and clinical profile can win on adoption. NVS's unsuccessful program should not be treated as broad validation for SRPT; modality-, construct-, and population-level differences matter, and the more relevant signal is whether clinicians become more cautious toward experimental neuromuscular interventions generally.

The contrarian view is that the apparent upside to sell-side targets may overstate risk-adjusted value because the next major program inflection is distant and the base business needs stabilization first. Conversely, the stock can outperform before definitive functional data if quarterly ELEVIDYS metrics demonstrate that the demand decline has bottomed, since that would reduce financing and execution concerns while preserving pipeline upside. Thesis is falsified positively by sequential product-sales recovery and sustained positive operating cash flow; it is falsified negatively by another material sales-guide cut, worsening safety/regulatory restrictions, or a biomarker update lacking durability or competitive separation.

Key Decisions for Investors

• Maintain SRPT as a watch-list long rather than chase at current levels: initiate only after the next earnings release shows sequential stabilization in ELEVIDYS net product revenue and management does not reduce full-year demand assumptions. Target a 20-30% rerating over 1-3 months on stabilization; exit on a second consecutive material product-sales deterioration or new label/safety constraint.
• For event exposure, prefer a defined-risk SRPT call spread dated beyond the expected second-half 2026 SRP-1003 update rather than outright equity. Structure sizing around the possibility of a 25-50% binary move, but do not pay for upside unless implied volatility is below the realized move priced by comparable neuromuscular data events.
• Monitor RNA as the cleaner relative-value hedge: long SRPT / short RNA only after SRPT reports functional evidence that is clearly differentiated from biomarker-only data. Without that evidence, avoid the pair because RNA may outperform if investors discount SRPT's commercialization timeline and favor its alternative platform.
• Set an immediate diligence alert for quarterly disclosures separating collaboration revenue, product revenue, gross-to-net changes, treatment-center inventory, and payer approvals. A profit beat without confirmation from these operating metrics should be sold into rather than interpreted as a fundamental turnaround.